These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15366680)

  • 1. [Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity].
    Bannwarth B
    Gastroenterol Clin Biol; 2004 Apr; 28 Spec No 3():C90-5. PubMed ID: 15366680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions].
    Bannwarth B
    Presse Med; 2002 Sep; 31(31):1469-75. PubMed ID: 12395741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in managing NSAID-associated gastrointestinal tract injury.
    Goldstein JL
    Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
    Lehmann FS; Beglinger C
    Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA; Derry S; McQuay HJ
    BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
    Wolfe MM
    Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroduodenal safety of cyclooxygenase-2 inhibitors.
    Scheiman JM
    Curr Pharm Des; 2003; 9(27):2197-206. PubMed ID: 14529400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF; van de Laar MA; Bijlsma JW
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1044-7. PubMed ID: 11414163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion.
    Hunt RH
    Can J Gastroenterol; 2003 May; 17(5):339-41. PubMed ID: 12772010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
    Hawkey CJ; Jackson L; Harper SE; Simon TJ; Mortensen E; Lines CR
    Aliment Pharmacol Ther; 2001 Jan; 15(1):1-9. PubMed ID: 11136272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment.
    Hawkey CJ
    Scand J Gastroenterol Suppl; 1996; 220():124-7. PubMed ID: 8898449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
    Naesdal J; Wilson I
    Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?
    Yuan Y; Hunt RH
    Inflammopharmacology; 2003; 11(4):337-54. PubMed ID: 15035788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ; Jensen DM; Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
    JAMA; 1999 Nov; 282(20):1929-33. PubMed ID: 10580458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.